Ginkgo Bioworks Holdings Pre-Tax Profit Margin 2020-2023 | DNA

Ginkgo Bioworks Holdings pre-tax profit margin from 2020 to 2023. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Ginkgo Bioworks Holdings Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2023-03-31 $0.39B $-1.73B -444.62%
2022-12-31 $0.48B $-2.12B -444.86%
2022-09-30 $0.53B $-3.54B -671.54%
2022-06-30 $0.54B $-2.97B -551.58%
2022-03-31 $0.44B $-2.36B -538.13%
2021-12-31 $0.31B $-1.84B -585.67%
2021-06-30 $0.10B $-0.16B -154.46%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.379B $0.478B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $137.942B 8.43
GSK (GSK) United Kingdom $69.839B 9.75
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
QIAGEN (QGEN) Netherlands $10.584B 22.35
Arcus Biosciences (RCUS) United States $1.536B 0.00
Biohaven (BHVN) United States $1.482B 0.00
Emergent Biosolutions (EBS) United States $0.416B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.191B 0.00
Enzo Biochem (ENZ) United States $0.110B 0.00
SQZ Biotechnologies (SQZ) United States $0.018B 0.00